Gilead accused of ripping off US taxpayers

pharmafile | March 28, 2019 | News story | Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents 

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in sales from preventative HIV drug Truvada, despite the fact it was developed  by the US government.

While the American government patented the PrEP drug in 2015, the government has not received a single penny in royalties from Foster City-based Gilead Sciences.

Nevertheless Gilead charge between $1,600 and $2,000 a month for Truvada. Meanwhile, generic versions of the drug are sold for as little as £20 for a month’s supply in the UK.

The high price has been a barrier to access and has meant the number of new HIV infections has stayed steady in the United States at a rate of around 40,000 a year.

As such, activists have called on the government to crack down on Gilead and other price gouging firms.

“The CDC has all these patents and is allowing Gilead to rip off the American people at the expense of public health,” said James Krellenstein, an HIV/AIDS activist and co-founder of the PrEP4All Collaboration.

“With the amount of effort and time and taxpayer money that went into it, for CDC and Gilead not to come to an agreement, so the taxpayer could get some of that money, is really unconscionable,” Thomas Folks, a former researcher at the U.S. Centers for Disease Control and Prevention lab said.

The dispute comes amid Donald Trump’s pledge to end the HIV epidemic by 2030. Widespread access to PrEP will be fundamental in achieving this goal.  

Louis Goss

Related Content

Gilead and Merck share data from phase 2 trial of HIV treatment

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …

Latest content